Positron emission tomography and cancer

Daniel N. Chatzifotiadis; Julia W. Buchanan; Richard L. Wahl

doi:10.1007/0-387-31056-8_33

Positron emission tomography and cancer

Daniel N. Chatzifotiadis, Julia W. Buchanan, Richard L. Wahl

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

2 Scopus citations

Abstract

Positron emission tomography, PET, is a potent imaging tool in the management of a diverse array of cancers. This chapter briefly discusses the rationale for PET imaging and describes how it differs from more typical anatomic imaging, reviews the principles of metabolic targeting with the radiolabeled glucose analogue ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), and then describes the clinical results of PET imaging in several types of common cancers. Although there are detailed descriptions of tumor imaging with other modalities in several areas of this textbook, the discussion here focuses on the role of PET.

Original language	English
Title of host publication	Oncology
Subtitle of host publication	An Evidence-Based Approach
Publisher	Springer New York
Pages	449-483
Number of pages	35
ISBN (Print)	0387242910, 9780387242910
DOIs	https://doi.org/10.1007/0-387-31056-8_33
State	Published - 2006

Access to Document

10.1007/0-387-31056-8_33

Cite this

@inbook{ce85d2ee95d343e9af991cdefdba02b2,

title = "Positron emission tomography and cancer",

abstract = "Positron emission tomography, PET, is a potent imaging tool in the management of a diverse array of cancers. This chapter briefly discusses the rationale for PET imaging and describes how it differs from more typical anatomic imaging, reviews the principles of metabolic targeting with the radiolabeled glucose analogue 18F-fluoro-2-deoxy-d-glucose (FDG), and then describes the clinical results of PET imaging in several types of common cancers. Although there are detailed descriptions of tumor imaging with other modalities in several areas of this textbook, the discussion here focuses on the role of PET.",

author = "Chatzifotiadis, {Daniel N.} and Buchanan, {Julia W.} and Wahl, {Richard L.}",

year = "2006",

doi = "10.1007/0-387-31056-8_33",

language = "English",

isbn = "0387242910",

pages = "449--483",

booktitle = "Oncology",

publisher = "Springer New York",

}

TY - CHAP

T1 - Positron emission tomography and cancer

AU - Chatzifotiadis, Daniel N.

AU - Buchanan, Julia W.

AU - Wahl, Richard L.

PY - 2006

Y1 - 2006

N2 - Positron emission tomography, PET, is a potent imaging tool in the management of a diverse array of cancers. This chapter briefly discusses the rationale for PET imaging and describes how it differs from more typical anatomic imaging, reviews the principles of metabolic targeting with the radiolabeled glucose analogue 18F-fluoro-2-deoxy-d-glucose (FDG), and then describes the clinical results of PET imaging in several types of common cancers. Although there are detailed descriptions of tumor imaging with other modalities in several areas of this textbook, the discussion here focuses on the role of PET.

AB - Positron emission tomography, PET, is a potent imaging tool in the management of a diverse array of cancers. This chapter briefly discusses the rationale for PET imaging and describes how it differs from more typical anatomic imaging, reviews the principles of metabolic targeting with the radiolabeled glucose analogue 18F-fluoro-2-deoxy-d-glucose (FDG), and then describes the clinical results of PET imaging in several types of common cancers. Although there are detailed descriptions of tumor imaging with other modalities in several areas of this textbook, the discussion here focuses on the role of PET.

UR - http://www.scopus.com/inward/record.url?scp=77955450002&partnerID=8YFLogxK

U2 - 10.1007/0-387-31056-8_33

DO - 10.1007/0-387-31056-8_33

M3 - Chapter

AN - SCOPUS:77955450002

SN - 0387242910

SN - 9780387242910

SP - 449

EP - 483

BT - Oncology

PB - Springer New York

ER -

Positron emission tomography and cancer

Abstract

Access to Document

Other files and links

Fingerprint

Cite this